Clinical Trials Browser

Interventional × Waldenstrom Macroglobulinemia × Clear all

NCT05294731 2026-04-17

Treatment of Chinese Participants With B-Cell Malignancies With BGB-16673, a Bruton Tyrosine Kinase-Targeted Protein-Degrader

Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Waldenstrom Macroglobulinemia, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

NCT01384513 2026-04-15

A Two-Step Approach to Reduced Intensity Bone Marrow Transplant for Patients With Hematological Malignancies

Phase 2 Completed

40 enrolled 15 charts

Classical hematologyDermatologicLymphoidMyeloidOther hematologic neoplasmPlasma cell

Pdgfra-Associated Chronic Eosinophilic Leukemia, Congenital Abnormalities, Anemia, Aplastic, Anemia, Refractory, Hodgkin Disease, Leukemia, Hairy Cell, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Waldenstrom Macroglobulinemia, Mastocytosis, Multiple Myeloma, Mycosis Fungoides, Myeloproliferative Disorders, Polycythemia Vera, Recurrence, Sezary Syndrome, Thrombocythemia, Essential, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Neutrophilic, Chronic, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic, Lymphoma, T-Cell, Cutaneous, Lymphoma, B-Cell, Marginal Zone, Leukemia, Large Granular Lymphocytic, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Lymphoma, Extranodal NK-T-Cell, Leukemia, Myelomonocytic, Juvenile, Primary Myelofibrosis

NCT05006716 2026-04-15

CaDAnCe-101

Phase 1/2 Recruiting

614 enrolled

LymphoidOther hematologic neoplasm

Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Waldenstrom Macroglobulinemia, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

NCT03192397 2026-04-14

Chemotherapy, Total Body Irradiation, and Post-Transplant Cyclophosphamide in Reducing Rates of Graft Versus Host Disease in Patients With Hematologic Malignancies Undergoing Donor Stem Cell Transplant

Phase 1/2 Active not recruiting

35 enrolled 19 charts

Classical hematologyLymphoidMyeloidOther hematologic neoplasmPlasma cell

Anemia, Aplastic, Graft vs Host Disease, Hodgkin Disease, Lymphoma, Non-Hodgkin, Waldenstrom Macroglobulinemia, Multiple Myeloma, Myelodysplastic Syndromes, Myeloproliferative Disorders, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Neoplasm, Residual

NCT05131022 2026-04-14

A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies

Phase 1 Recruiting

572 enrolled

LymphoidOther hematologic neoplasm

Lymphoma, Lymphoma, Follicular, Waldenstrom Macroglobulinemia, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

NCT06544265 2026-04-14

SynKIR-310 for Relapsed/Refractory B-NHL

Phase 1 Recruiting

36 enrolled

LymphoidSarcoma

Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Waldenstrom Macroglobulinemia, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell, Pyloric Stenosis, Hypertrophic, Dendritic Cell Sarcoma, Interdigitating

NCT01804686 2026-04-13

CAN3001

Phase 3 Recruiting

700 enrolled

LymphoidOther hematologic neoplasm

Bronchiolitis Obliterans Syndrome, Lymphoma, Follicular, Waldenstrom Macroglobulinemia, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Mantle-Cell

NCT04728893 2026-04-13

MK-1026-003

Phase 2 Recruiting

490 enrolled

LymphoidOther hematologic neoplasm

Lymphoma, Non-Hodgkin, Waldenstrom Macroglobulinemia, Leukemia, B-Cell, Hematologic Neoplasms

Clinical Trials

Treatment of Chinese Participants With B-Cell Malignancies With BGB-16673, a Bruton Tyrosine Kinase-Targeted Protein-Degrader

A Two-Step Approach to Reduced Intensity Bone Marrow Transplant for Patients With Hematological Malignancies

CaDAnCe-101

Chemotherapy, Total Body Irradiation, and Post-Transplant Cyclophosphamide in Reducing Rates of Graft Versus Host Disease in Patients With Hematologic Malignancies Undergoing Donor Stem Cell Transplant

A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies

SynKIR-310 for Relapsed/Refractory B-NHL

CAN3001

MK-1026-003

Testing the Combination of Venetoclax and Rituximab, in Comparison to the Usual Treatment (Ibrutinib Plus Rituximab or Zanubrutinib Alone) for Waldenstrom's Macroglobulinemia/Lymphoplasmacytic Lymphoma

Study to Assess Change in Disease Activity of Oral Venetoclax in Adult Participants With Recurring Relapsed or Refractory (R/R) Waldenström Macroglobulinemia (WM)/Lymphoplasmacytic Lymphoma (LPL)

Long-term Follow-up Study for Patients Treated With CLBR001 CAR-T

A Phase II Study of Carfilzomib in Relapsed Waldenström's Macroglobulinemia (WM) IST-CAR-531

ZEBRA

Study to Evaluate Adverse Events, Change in Disease Activity, and How Oral ABBV-101 Moves Through the Body in Adult Participants With B-Cell Malignancies

Rituxan/Bendamustine/PCI-32765 in Relapsed DLBCL, MCL, or Indolent Non-Hodgkin's Lymphoma

An Open-label, Phase 2 Study of ACP-196 in Subjects With Waldenström Macroglobulinemia

A Study of NX-2127 in Adults With Relapsed/Refractory B-cell Malignancies

CLOVER-WaM

BLOOD-dose

Epcoritamab in Previously Treated WM

Bortezomib and Rituximab for Patients With Waldenstrom's Macroglobulinemia

Lenalidomide and Combination Chemotherapy (DA-EPOCH-R) in Treating Patients With MYC-Associated B-Cell Lymphomas

Nemtabrutinib, Bortezomib, and Rituximab for WM

ZUMA-25

Ixazomib Citrate and Rituximab in Treating Patients With Indolent B-cell Non-Hodgkin Lymphoma

Ibrutinib and Ixazomib Citrate in Treating Newly Diagnosed, Relapsed or Refractory Waldenstrom Macroglobulinemia

Study of Oral LOXO-338 in Patients With Advanced Blood Cancers

Dose Escalation and Dose Expansion Study of MDX2003 in Patients With Different Types of Lymphoma

Cosibelimab for CSCC in Patients With Kidney Transplant or Hematologic Malignancy

A Study of APG-3288 in Relapsed/Refractory Blood Cancers

ABBV-383 for the Treatment of Relapsed Refractory Waldenström Macroglobulinemia

Study of Oral Administration of LP-168 in Patients With Relapsed or Refractory B-cell Malignancies.

Study of SGR-1505 in Mature B-Cell Neoplasms

BDH-WM02

BDH-WM01

BDH-WM03

Zanubrutinib, Ixazomib and Dexamethasone in Patients With Treatment Naive Waldenstrom's Macroglobulinemia

BRAWM

Zanubrutinib (BGB-3111) in Participants With Previously Treated B-Cell Lymphoma Intolerant of Prior Bruton Tyrosine Kinase Inhibitor (BTKi) Treatment

A Study of Oral LOXO-305 in Patients With Previously Treated CLL/SLL or NHL

A Study to Investigate Efficacy and Safety of BCL2 Inhibitor Sonrotoclax as Monotherapy and in Combination With Zanubrutinib in Adults With Waldenström Macroglobulinemia

A Study to Evaluate the Efficacy and Safety of Zanubrutinib in Chinese Adults With Treatment-Naive Waldenström Macroglobulinemia

KEYNOTE145

AS-1763 in Patients With Previously Treated CLL/SLL or Non-Hodgkin Lymphoma

Efficacy of First Line B-RI for Treatment Naive Waldenström's Macroglobulinemia

ACALA-R In Predominantly Demyelinating IgM Mediated Neuropathy

A Phase 2 Study to Evaluate the Safety and Efficacy of Pacritinib in Relapsed or Refractory Waldenström Macroglobulinemia

ZBR in WM

RV-WM-0426

VIWA-1